Sanofi Puts Up €300M in New Targeted Radiation Cancer Therapy Pact With Orano

Sanofi’s equity investment in the new Orano Med entity comes a month after the pharmaceutical giant struck a €100 million deal to license a clinical-stage radiopharmaceutical developed for neuroendocrine tumors. Orano Med develops targeted cancer therapies based on lead-212, an alpha-emitting isotope. The post Sanofi Puts Up €300M in New Targeted Radiation Cancer Therapy Pact…

Read More

Function Health has a 23andMe problem

By DEEKSHA HEGDE I had an itch to draw parallels between the two. The structural facts kept lining up in ways I couldn’t dismiss, and by the end, I stopped trying. Function’s product is an app: you pay $365 a year, go to a Quest Diagnostics location, get 160+ biomarkers tested twice a year, and…

Read More

The People — And Research — Lost in the NIH Exodus

‘No Longer Based on Facts or Truth’ Sylvia Chou, 51, Maryland Program director, National Cancer Institute Sylvia Chou specializes in communication between patients and their health care providers, and social media’s role in public health. She joined the federal government in 2007 as a fellow and became a civil servant in 2010. She left her…

Read More